NL8900525A - Geneesmiddelen die sufotidine bevatten alsmede de toepassing daarvan. - Google Patents

Geneesmiddelen die sufotidine bevatten alsmede de toepassing daarvan. Download PDF

Info

Publication number: NL8900525A
Authority: NL; Netherlands
Prior art keywords: sufotidine; piroxicam; steroidal anti; pharmaceutical preparation; free base
Prior art date: 1988-03-04

Application number

NL8900525A

Other languages

English (en)

Dutch (nl)

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-03-04

Filing date

1989-03-03

Publication date

1989-10-02

1989-03-03 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1989-10-02 Publication of NL8900525A publication Critical patent/NL8900525A/nl

Links

JEYKZWRXDALMNG-UHFFFAOYSA-N sufotidine Chemical compound CN1N=C(CS(C)(=O)=O)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 JEYKZWRXDALMNG-UHFFFAOYSA-N 0.000 title claims description 38
229950002504 sufotidine Drugs 0.000 title claims description 38
239000003814 drug Substances 0.000 title claims description 10
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 24
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 16
229960002702 piroxicam Drugs 0.000 claims description 15
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 15
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 13
229960000905 indomethacin Drugs 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
239000000825 pharmaceutical preparation Substances 0.000 claims description 11
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 9
239000012458 free base Substances 0.000 claims description 9
229960001680 ibuprofen Drugs 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 8
230000009885 systemic effect Effects 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 8
230000004968 inflammatory condition Effects 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 5
229960001138 acetylsalicylic acid Drugs 0.000 claims description 5
-1 fenprofen Chemical compound 0.000 claims description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
229960001671 azapropazone Drugs 0.000 claims description 3
WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 claims description 3
229960004277 benorilate Drugs 0.000 claims description 3
FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 claims description 3
238000007796 conventional method Methods 0.000 claims description 3
229960001395 fenbufen Drugs 0.000 claims description 3
ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 claims description 3
IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 claims description 3
229950006236 fenclofenac Drugs 0.000 claims description 3
229960000489 feprazone Drugs 0.000 claims description 3
229960004369 flufenamic acid Drugs 0.000 claims description 3
LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims description 3
229960002390 flurbiprofen Drugs 0.000 claims description 3
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 3
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 3
229960000991 ketoprofen Drugs 0.000 claims description 3
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
229960003464 mefenamic acid Drugs 0.000 claims description 3
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 3
229960002009 naproxen Drugs 0.000 claims description 3
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 3
229960002895 phenylbutazone Drugs 0.000 claims description 3
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
229940095064 tartrate Drugs 0.000 claims description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
229960001259 diclofenac Drugs 0.000 claims description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
238000000034 method Methods 0.000 claims description 2
239000008024 pharmaceutical diluent Substances 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
229960000616 diflunisal Drugs 0.000 claims 2
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 2
229960000649 oxyphenbutazone Drugs 0.000 claims 2
HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 claims 2
229960000894 sulindac Drugs 0.000 claims 2
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 2
229960001017 tolmetin Drugs 0.000 claims 2
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
235000019359 magnesium stearate Nutrition 0.000 description 11
239000000203 mixture Substances 0.000 description 9
229920002472 Starch Polymers 0.000 description 7
239000008107 starch Substances 0.000 description 7
229940032147 starch Drugs 0.000 description 7
235000019698 starch Nutrition 0.000 description 7
239000000829 suppository Substances 0.000 description 7
239000002775 capsule Substances 0.000 description 6
239000004480 active ingredient Substances 0.000 description 5
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
239000002260 anti-inflammatory agent Substances 0.000 description 4
238000007906 compression Methods 0.000 description 4
230000006835 compression Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
229940121363 anti-inflammatory agent Drugs 0.000 description 3
239000008187 granular material Substances 0.000 description 3
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000023178 Musculoskeletal disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
239000002585 base Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
229960001419 fenoprofen Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
201000000052 gastrinoma Diseases 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229920003087 methylethyl cellulose Polymers 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000009854 mucosal lesion Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
208000000689 peptic esophagitis Diseases 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

NL8900525A 1988-03-04 1989-03-03 Geneesmiddelen die sufotidine bevatten alsmede de toepassing daarvan. NL8900525A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB888805268A GB8805268D0 (en)	1988-03-04	1988-03-04	Medicaments
GB8805268		1988-03-04

Publications (1)

Publication Number	Publication Date
NL8900525A true NL8900525A (nl)	1989-10-02

Family

ID=10632893

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8900525A NL8900525A (nl)	1988-03-04	1989-03-03	Geneesmiddelen die sufotidine bevatten alsmede de toepassing daarvan.

Country Status (12)

Country	Link
JP (1)	JP2834175B2 (ja)
KR (1)	KR890014110A (ja)
AU (1)	AU3098489A (ja)
BE (1)	BE1002256A3 (ja)
DE (1)	DE3906884A1 (ja)
DK (1)	DK104489A (ja)
FR (1)	FR2627985A1 (ja)
GB (2)	GB8805268D0 (ja)
IT (1)	IT8947714A0 (ja)
NL (1)	NL8900525A (ja)
SE (1)	SE8900752L (ja)
ZA (1)	ZA891640B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO300260B1 (no)	1993-05-05	1997-05-05	Torgersen Hans & Soenn	Bilbarnestol
MY164077A (en) *	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
EP1214056B1 (en) *	1999-09-24	2003-10-29	Alcon Inc.	Topical suspension formulations containing ciprofloxacin and dexamethasone
US8206741B2 (en)	2001-06-01	2012-06-26	Pozen Inc.	Pharmaceutical compositions for the coordinated delivery of NSAIDs
EA201100313A1 (ru)	2008-09-09	2011-10-31	Астразенека Аб	Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
CA2764963C (en)	2009-06-25	2016-11-01	Astrazeneca Ab	Method for treating a patient at risk for developing an nsaid-associated ulcer
BR112014016085A8 (pt)	2011-12-28	2017-07-04	Pozen Inc	composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH655104A5 (fr) *	1980-02-28	1986-03-27	Glaxo Group Ltd	Derives heterocycliques triazoliques, procedes pour leur preparation et compositions pharmaceutiques les comportant.
BE894286A (fr) *	1981-09-04	1983-03-02	Glaxo Group Ltd	Composition pharmaceutique contenant un medicament anti-inflammatoire systemique non steroidique et du 1-methyl-5-((3-(3-(1-piperidinylmethyl)phenoxy)-propyl)amino -1h-1,2,4-triazole-3-methanol ou un sel de ce compose
CY1398A (en) *	1981-09-04	1987-12-18	Glaxo Group Ltd	Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
US4783465A (en) *	1984-04-09	1988-11-08	Analgesic Associates	Cough/cold mixtures comprising non-sedating antihistamine drugs

1988
- 1988-03-04 GB GB888805268A patent/GB8805268D0/en active Pending
1989
- 1989-03-03 AU AU30984/89A patent/AU3098489A/en not_active Abandoned
- 1989-03-03 DE DE3906884A patent/DE3906884A1/de not_active Withdrawn
- 1989-03-03 FR FR8902778A patent/FR2627985A1/fr not_active Withdrawn
- 1989-03-03 DK DK104489A patent/DK104489A/da not_active Application Discontinuation
- 1989-03-03 GB GB8904879A patent/GB2216413A/en not_active Withdrawn
- 1989-03-03 SE SE8900752A patent/SE8900752L/xx not_active Application Discontinuation
- 1989-03-03 JP JP1051813A patent/JP2834175B2/ja not_active Expired - Lifetime
- 1989-03-03 BE BE8900222A patent/BE1002256A3/fr not_active IP Right Cessation
- 1989-03-03 KR KR1019890002612A patent/KR890014110A/ko not_active Withdrawn
- 1989-03-03 IT IT8947714A patent/IT8947714A0/it unknown
- 1989-03-03 ZA ZA891640A patent/ZA891640B/xx unknown
- 1989-03-03 NL NL8900525A patent/NL8900525A/nl not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2834175B2 (ja)	1998-12-09
DK104489D0 (da)	1989-03-03
SE8900752L (sv)	1989-09-05
DE3906884A1 (de)	1989-09-14
KR890014110A (ko)	1989-10-21
SE8900752D0 (sv)	1989-03-03
ZA891640B (en)	1990-03-28
JPH01316319A (ja)	1989-12-21
FR2627985A1 (fr)	1989-09-08
GB8904879D0 (en)	1989-04-12
AU3098489A (en)	1989-09-07
IT8947714A0 (it)	1989-03-03
GB8805268D0 (en)	1988-04-07
DK104489A (da)	1989-09-05
GB2216413A (en)	1989-10-11
BE1002256A3 (fr)	1990-11-06

Legal Events

Date	Code	Title	Description
1991-11-01	BV	The patent application has lapsed

Publication	Publication Date	Title
US20210113469A1 (en)	2021-04-22	Sustained release compositions using wax-like materials
US6544556B1 (en)	2003-04-08	Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
KR100483870B1 (ko)	2005-09-30	양성자펌프억제제및비스테로이드성항염증약물을포함하는경구제약제형
AU606149B2 (en)	1991-01-31	Pharmaceutical formulations
WO2000028980A2 (en)	2000-05-25	Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain
JPH04501425A (ja)	1992-03-12	ロラタジン、イブプロフェンおよびプソイドエフェドリンを含む薬剤組成物
GB2105193A (en)	1983-03-23	Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
AP324A (en)	1994-03-07	Medicaments for treating inflammatory conditions or for analgiesia.
US20110086074A1 (en)	2011-04-14	Combinations of niacin and an oxicam
GB2216413A (en)	1989-10-11	Medicaments containing sufotidine
KR0175345B1 (ko)	1999-02-18	장점막 장애 예방 및 치료제
NL193821C (nl)	2000-12-04	Farmaceutisch preparaat.
JPH0296525A (ja)	1990-04-09	医薬
CA1315690C (en)	1993-04-06	Synergistic combination of decarboxylase inhibitors and l-dopa pellets
WO2019130049A1 (en)	2019-07-04	Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain
US20100143471A1 (en)	2010-06-10	Novel reduced dose pharmaceutical compositions of fexofenadine and pseudoephedrine
EP0182569B1 (en)	1992-01-29	Use of 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4H-pyrido[1,2-a]pyrimidine-3-carboxamide for the prevention and treatment of gastrointestinal damages
JP2015514799A (ja)	2015-05-21	サルサレートの遅延放出性医薬組成物
SK19192000A3 (sk)	2001-05-10	Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia
GB2105588A (en)	1983-03-30	Pharmaceutical compositions containing non-steroidal anti- inflammatory agents
JP4430312B2 (ja)	2010-03-10	医薬製剤
MXPA00012626A (en)	2001-07-31	Method of treatment
BRPI0707736A2 (pt)	2011-05-10	formulaÇÕes de imidazolilalquil-piridinas de dosagem estÁvel